| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA289614
Max Phase: Preclinical
Molecular Formula: C32H40N4O4S
Molecular Weight: 576.76
Molecule Type: Small molecule
Associated Items:
Representations
Synonyms (1): L-162782
Synonyms from Alternative Forms(1):
Canonical SMILES: CCCCOC(=O)NS(=O)(=O)c1ccc(CC(C)C)cc1-c1ccc(Cn2c(CC)nc3c(C)cc(C)nc32)cc1
Standard InChI: InChI=1S/C32H40N4O4S/c1-7-9-16-40-32(37)35-41(38,39)28-15-12-25(17-21(3)4)19-27(28)26-13-10-24(11-14-26)20-36-29(8-2)34-30-22(5)18-23(6)33-31(30)36/h10-15,18-19,21H,7-9,16-17,20H2,1-6H3,(H,35,37)
Standard InChI Key: GABMQILPAPONQS-UHFFFAOYSA-N
Associated Targets(Human)
Angiotensin II type 2 (AT-2) receptor 2549 Activities
Type-1 angiotensin II receptor 5176 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Associated Targets(non-human)
Angiotensin II receptor (AT-1) type-1 1480 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Type-1A angiotensin II receptor 520 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Type-1 angiotensin II receptor 25 Activities
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 576.76 | Molecular Weight (Monoisotopic): 576.2770 | AlogP: 6.74 | #Rotatable Bonds: 11 |
| Polar Surface Area: 103.18 | Molecular Species: ACID | HBA: 7 | HBD: 1 |
| #RO5 Violations: 2 | HBA (Lipinski): 8 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 2 |
| CX Acidic pKa: 2.82 | CX Basic pKa: 3.57 | CX LogP: 6.87 | CX LogD: 6.76 |
| Aromatic Rings: 4 | Heavy Atoms: 41 | QED Weighted: 0.20 | Np Likeness Score: -1.01 |
References
| 1. Wan Y, Wallinder C, Johansson B, Holm M, Mahalingam AK, Wu X, Botros M, Karlén A, Pettersson A, Nyberg F, Fändriks L, Hallberg A, Alterman M.. (2004) First reported nonpeptide AT1 receptor agonist (L-162,313) acts as an AT2 receptor agonist in vivo., 47 (6): [PMID:14998339] [10.1021/jm031031i] |
| 2. Wallinder C, Botros M, Rosenström U, Guimond MO, Beaudry H, Nyberg F, Gallo-Payet N, Hallberg A, Alterman M.. (2008) Selective angiotensin II AT2 receptor agonists: Benzamide structure-activity relationships., 16 (14): [PMID:18599297] [10.1016/j.bmc.2008.05.066] |
| 3. Wallinder C, Sköld C, Botros M, Guimond MO, Hallberg M, Gallo-Payet N, Karlén A, Alterman M.. (2015) Interconversion of Functional Activity by Minor Structural Alterations in Nonpeptide AT2 Receptor Ligands., 6 (2): [PMID:25699147] [10.1021/ml500427r] |
| 4. Sallander J, Wallinder C, Hallberg A, Åqvist J, Gutiérrez-de-Terán H.. (2016) Structural determinants of subtype selectivity and functional activity of angiotensin II receptors., 26 (4): [PMID:26810314] [10.1016/j.bmcl.2015.10.084] |
| 5. Dosa PI, Amin EA.. (2016) Tactical Approaches to Interconverting GPCR Agonists and Antagonists., 59 (3): [PMID:26390077] [10.1021/acs.jmedchem.5b00982] |
Source
Source(1):